Form 4: Akero Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold shares of common stock on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 5, 2025, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, sold shares of the company's common stock.
• The sales were executed under a previously adopted Rule 10b5-1 trading plan dated August 12, 2024.
• A total of 18,750 shares were acquired through the exercise of stock options at a price of $21.10 per share.
• Rolph sold 12,847 shares at a weighted-average price of $56.325, with individual transactions ranging from $55.68 to $56.67.
• An additional 5,903 shares were sold at a weighted-average price of $56.924, with individual transactions ranging from $56.68 to $57.25.
• Following these transactions, Rolph directly owns 170,237 shares of Akero Therapeutics common stock.
• Rolph also owns 47,468 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports stock sales under a pre-existing trading plan, which is a routine activity.

Industry Context

Executive stock sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Akero Therapeutics, Timothy Rolph, stock sale, Form 4, Rule 10b5-1, insider trading, AKRO, Chief Scientific Officer, stock options